The reduction is the second time that BG Medicine has lowered the expected price for its IPO, which is now less than 40 percent of what it originally targeted.
The company hopes to raise enough capital in the IPO to pay for that bill, which covers phase I and II trials for its lead candidates. It also said R&D costs decreased over the first nine months of 2010 while revenues rose for the period year over year.
An article about an acquisition topped the list of the most-read stories for the year on GenomeWeb Daily News, while restructurings, lawsuits, and one firm's IPO plans made it into the top 10.